The estimated Net Worth of Charlotte C. Arnold is at least $5.56 Million dollars as of 25 September 2015. Charlotte Arnold owns over 19,060 units of ANI Pharmaceuticals Inc stock worth over $2,721,323 and over the last 11 years Charlotte sold ANIP stock worth over $2,835,000.
Charlotte has made over 5 trades of the ANI Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Charlotte exercised 19,060 units of ANIP stock worth $145,047 on 25 September 2015.
The largest trade Charlotte's ever made was selling 45,000 units of ANI Pharmaceuticals Inc stock on 12 March 2015 worth over $2,835,000. On average, Charlotte trades about 2,549 units every 6 days since 2013. As of 25 September 2015 Charlotte still owns at least 50,098 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Charlotte Arnold stock trades at the bottom of the page.
Charlotte's mailing address filed with the SEC is 210 MAIN STREET WEST, C/O ANI PHARMACEUTICALS, INC., BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri..., and Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: